COMPANY PROFILE

ORIC Pharmaceuticals

ORIC Pharmaceuticals Inc operates as a biopharmaceutical company

South San Francisco, United StatesFounded 2014Biotech & Life Sciences

Valuation $1.12B Market cap · 2026

Total funding $100–500M Disclosed equity funding

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies to overcome resistance in cancer treatment. The company's lead product candidate, ORIC-101, is a glucocorticoid receptor (GR) antagonist currently in Phase 1b clinical trials. GR is often overexpressed in multiple solid tumors and is associated with poorer outcomes, making it a critical target for cancer therapy. By blocking GR activity, ORIC-101 aims to improve patient outcomes and combat resistance to existing treatments.

Read full description

ORIC Pharmaceuticals operates in the oncology market, primarily serving patients with advanced or metastatic solid tumors. The company employs a research-driven business model, investing heavily in preclinical and clinical trials to validate its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.

The company is also exploring other promising candidates, such as a CD73 inhibitor, to further expand its pipeline. ORIC Pharmaceuticals aims to address significant unmet medical needs in oncology by targeting the underlying mechanisms of resistance.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: South San Francisco, United States
Listing: IPO 2020
Employees: 137
Open positions: 4
Dealroom signal: 74.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Oncology, Research and Development, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Feb 2026	$264M	—	Undisclosed	↗
PRIVATE PLACEMENT VCOther financing	May 2025	$125M	—	NEA · SR One · Viking Global Investors · Nextech	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$0	—	−$165M	—
2025	$0	—	−$142M	—
2024	$0	—	−$142M	—
2023	$0	—	−$110M	—
2022	$0	—	−$82M	—
2021	$0	—	−$79M	—
2020	$0	—	−$25M	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

ORIC Pharmaceuticals website traffic

Latest recorded traffic for ORIC Pharmaceuticals is 6.8K monthly website visits, up 30.8% over the last three months. ORIC Pharmaceuticals's team grew 6.2% over the past year.

Latest monthly visits6.8K 3-month web change+30.8% 1-year team growth+6.2%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Quality Systems Associate (Contract)San Diego, California, United States, Northern America, Americas · Other · Sep 1, 2026 Quality Assurance AssociateSan Diego, CA · Business Intelligence · Jul 10, 2026 Director/Associate Director, Regulatory AffairsSan Diego, California, United States, Northern America, Americas · Other · Jun 20, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNxera Pharma UK \| Heptares TherapeuticsDevelops novel, small-molecule drugs for G-protein-coupled receptors	Great Abington, United Kingdom	Acquired	—	$59M	$400M
MEMedivationBiopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases	San Francisco, United States	Acquired
IMImcyseSpecific immunotherapies for severe autoimmune diseases	Liège, Belgium	Operational
TUTubulisGenerates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology	Planegg, Germany	Acquired
GEGenoskinFirst-in-human data to accelerate drug development	Salem, United States	Operational
PRProfionicsInnovative diagnostic solutions leveraging biomarkers and AI to rapidly detect and treat sepsis	Stevenage, United Kingdom	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational
GBGennao BioGennao Bio is pioneering the development of targeted nucleic acid therapeutics using its unique, non-viral GMAB platform technology	Hopewell, United States	Operational